Long‐Term Valproate and Lamotrigine Treatment May Be a Marker for Reduced Growth and Bone Mass in Children with Epilepsy

@article{Guo2001LongTermVA,
  title={Long‐Term Valproate and Lamotrigine Treatment May Be a Marker for Reduced Growth and Bone Mass in Children with Epilepsy},
  author={C. Y. Guo and G. Ronen and S. Atkinson},
  journal={Epilepsia},
  year={2001},
  volume={42}
}
  • C. Y. Guo, G. Ronen, S. Atkinson
  • Published 2001
  • Medicine
  • Epilepsia
  • Summary:  Purpose: To determine whether long‐term treatment with valproate (VPA) and/or lamotrigine (LTG) in children with epilepsy is associated with altered growth and/or bone metabolism. 
    171 Citations
    Levetiracetam, Phenytoin, and Valproate Act Differently on Rat Bone Mass, Structure, and Metabolism
    • 92
    • Highly Influenced
    Endocrine Effects of Valproate in Adolescent Girls with Epilepsy
    • 31
    • Highly Influenced
    Adverse effects of valproate on bone: Defining a model to investigate the pathophysiology
    • 34
    • Highly Influenced
    Impaired bone and muscle development in young people treated with antiepileptic drugs
    • 10
    The Effect of Oxcarbazepine on Bone Metabolism
    • 17
    Clinical significance of CYP2C9‐status guided valproic acid therapy in children
    • 33
    • PDF

    References

    SHOWING 1-10 OF 40 REFERENCES
    Osteomalacia with Long-term Anticonvulsant Therapy in Epilepsy
    • 375
    • PDF
    Effect of Antiepileptic Drugs on Bone Mineral Density in Children Between Ages 6 and 2 Years
    • 104
    Evaluation of bone mineral density in children receiving antiepileptic drugs.
    • 101
    • Highly Influential
    Strategies to protect bone mass in the older patient with epilepsy.
    • 15
    Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status.
    • 78
    • PDF
    Pathophysiology behind anticonvulsant osteomalacia.
    • 21